There’s two ways of looking at this …
They wanted to give an opportunity for long term shareholders to participate at a low cost as this will be the last chance before the interim results are known.
If successful …
At that point it will no longer be shareholders funding any further .
It’s good to know …. In March 2024, the Company updated the market to report that 11 patients had
been dosed in the Phase 2a trial at that time
.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.8¢ |
Change
-0.003(1.04%) |
Mkt cap ! $116.7M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 24.5¢ | 23.8¢ | $900.9K | 3.728M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 248135 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 80927 | 6 |
View Market Depth
| Last trade - 15.49pm 31/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |